{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-349136","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2026-08-13T20:04:52+00:00","discovered_at":"2026-08-13T20:06:01.680170+00:00","generated_at":"2026-08-13T20:06:11.029014+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CV Sciences Q2 2026 revenue down 17.5% to $3.0M; adjusted EBITDA turns negative","bullets":["Revenue $3.0M, down 17.5% YoY from $3.6M; gross margin 48.6% vs 50.9% prior year.","Operating loss widened to $0.3M from $0.1M; adjusted EBITDA turned negative at -$0.1M vs +$0.1M.","Cash balance $0.3M; operating expenses cut 11.3% YoY to $1.7M.","44% of net revenue from new products launched since Jan 2023; 52 new products launched; launched PlusHLTH.com e-commerce.","U.S. Senate voted 61-32 on H.R. 6500 delaying restrictive hemp-derived cannabinoid provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-349136","json":"https://secwatch.observer/filing/0001193125-26-349136.json","markdown":"https://secwatch.observer/filing/0001193125-26-349136.md","text":"https://secwatch.observer/filing/0001193125-26-349136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/0001193125-26-349136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000119312526349136/cvsi-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:06:11.029014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}